Bioquell Rapid Bio Decontamination Service (RBDS) enables businesses to quickly regain control of clean spaces and ramp up capacity As the world prepares to enter the next phase of the COVID-19 pandemic with the potential relaxation of lockdown restrictions, Bioquell, an Ecolab solution and leading manufacturer of high performance bio-decontamination technology, is utilizing its well-proven […]Read More
Following the COVID-19 lockdown, environmental monitoring at a major international provider of Biologics Contract Development and Manufacturing Organisations (CDMO) services in Wuhan, China indicated spore contamination in a production room. Despite exhausting all disinfection methods in its records, including the manual application of a sporicide, there was a repeated failure of the EM test standards. […]Read More
During the COVID-19 pandemic, many hospital wards were temporarily converted to solely treat COVID-19 patients. As these begin to revert back to ‘regular’ non COVID-19 wards, a solution is required to manage the increased potential contamination risk facing the patients admitted to these wards. Our latest case study highlights how Bioquell’s RBDS recently returned an […]Read More
One of New Zealand’s largest hospitals has chosen to purchase their first Bioquell BQ-50 suite to help them combat COVID-19. The hospital is well versed in performing airborne disinfection with alternative technologies but has selected Bioquell to improve their decontamination capabilities. The Bioquell BQ-50 has been chosen due to its emphasis on operator and patient […]Read More
A hospital in Kent has recently purchased 3 Bioquell PODs after identifying that their current set-up was not adequate for viral or bacterial infection outbreaks. The plan is to transform part of their High Dependency Unit into segregated areas using the Bioquell PODs. The Bioquell POD is an ideal solution for converting open wards to […]Read More
Join Bioquell at booth 1804 at BioProcess International during Biotech Week Boston which will bring together more than 2,000 scientists, engineers and executives working across the entire spectrum of biopharmaceutical development and production.